To examine the cost-effectiveness of a community-based screening programme for chronic atrial brillation (AF) in Japan.
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M
any epidemiological studies have demonstrated that chronic atrial brillation (AF) is an independent risk factor for ischaemic stroke. [1] [2] [3] In an effort to decrease this risk, the ef cacy of anticoagulant therapy has been examined in randomised controlled trials (RCT). [4] [5] [6] [7] [8] [9] Based on the favourable results from these trials, strong recommendations have been made for the use of anticoagulants in patients with AF. [10] [11] [12] Unfortunately, ischaemic stroke is often the rst sign of the arrhythmia in patients with AF. 13 Therefore, a communitywide screening programme to nd out patients with undetected AF could be worthwhile to conduct. 14 In Japan, annual ECG screening for community residents has been performed since 1983, 15 and AF is not an uncommon nding. The cost-effectiveness of this type of screening programme, however, has not been veri ed. We therefore conducted a cost-utility analysis of an annual community screening programme using ECG or pulse palpation for detecting patients with AF.
METHODS

Model Design
Cost-effectiveness analysis and sensitivity analyses were done using the Markov model ( Figure 1 ) by computer programme DATA 3.5 for Healthcare software (TreeAge Software, Inc., Williamstown, Massachusetts). The target population in this simulation model were 65-year-old males or females residing in Japan, who were followed until 85 years of age.
We compared three strategies: annual screening with ECG, annual screening with pulse palpation for arrhythmia followed by ECG when arrhythmia was detected, and no screening.
A bene t in this model was risk reduction of ischaemic stroke in patients with AF due to early detection and intervention. Costs computed were the examination cost in screening and time cost of attending screening programme, direct medical costs, and disability care costs. The perspective on this study was societal. 16 In designing the Markov model, we made the following assumptions to simulate the progression of clinical events in the community. Some residents with sinus rhythm develop AF. Some of them are detected when they visit clinics or hospitals because of other reasons (i.e. case-nding) and they do not participate in the screening programme. Patients with undetected AF develop persistent AF (or permanent AF in future) and participate in the annual screening programme (i.e., screening detection). Some of these patients develop ischaemic stroke with or without neurological sequelae and some die.
Assumptions for the screening programme are as follows. ECG can diagnose AF perfectly, while palpation of the radial pulse performed by physicians for one minute has false positive and false negative results in detecting AF. We did not consider other abnormal ECG ndings in this model because they do not satisfy the criteria to carry out screening, 17 in terms of diagnostic accuracy of target diseases and effectiveness of early intervention.
Assumptions regarding follow-up are as follows. Once diagnosed as having AF, the patients visit clinics to undergo echocardiography and anticoagulant therapy with international normalized ratio (INR) monitoring repeated bimonthly. Anticoagulant therapy decreases the risk of ischaemic stroke but increases the risks of intracranial haemorrhage (ICH) and gastrointestinal haemorrhage. Some of the patients not on anticoagulants develop ischaemic stroke followed by the implementation of anticoagulant therapy. After ICH, the patients stop anticoagulant therapy.
The following major health states were considered in the Markov model:
r Healthy with sinus rhythm r Healthy with AF r Ischaemic stroke without disability r Ischaemic stroke with disability r Repeated disabling ischaemic stroke r ICH without disability r ICH with disability r Disabling ischaemic stroke and disabling ICH r Deceased.
Patients who had repeated disabling ischaemic stroke or ICH were presumed to die if they developed another episode of ischaemic stroke.
Probabilities and Rates
The prevalence of AF at 65 years old 18 and the age-related incidences of AF were derived from the Framingham study 19 that covered 55-94 year old residents. This is because data about the age-related incidence of AF in Japan was available only for those aged 40-69 years old. 20 Fortunately, the incidence of AF in the Framingham study for individuals aged 65-74 years old (0.85%/person-year) was compatible with the incidence from the cohort study in Japan for individuals 60-69 years old (0.54-0.88%/person-year). In the Framingham study, AF was detected either by case-nding or by screening. We assume the same in our model, i.e. that newly developed AF was detected either by case-nding or by screening, with their proportions the same as those in the Framingham study. 21 The incidence of ischaemic stroke in patients with AF was derived from the Framingham study (Table 1) . 21 The mortality rate of ischaemic stroke and the proportion of disabling ischaemic stroke among all ischaemic strokes were matched to the gures used in the cost-effectiveness analysis by Eckman et al. 22 We obtained the risk reduction in ischaemic stroke with anticoagulant therapy and the incidence of ICH due to anticoagulant therapy from the metaanalysis recently conducted by Hart et al. 23 on RCTs of anticoagulants prophylaxis. We estimated the incidence of gastrointestinal haemorrhage due to anticoagulant therapy based on the incidence of major extracranial haemorrhage reported in the meta-analysis. We also took into consideration age-related mortality in the general population (Ministry of Health and Welfare, http://www.mhlw.go.jp/).
The sensitivity and speci city of palpation of the pulse for detecting AF were derived from the cross-sectional study by Somerville et al. 24 In that study, nurses performed a pulse check on the brachial artery for approximately one minute. We assumed that ECG is a gold standard of diagnosis for AF.
In base-case analysis, we set the attendance rate for the screening programme, clinic visit rate after detecting AF and anticoagulant prescription rate as 100%. In sensitivity analyses, we decreased these values to 50%, 50% and 30%, respectively.
Utility
We made adjustments in our assumptions regarding quality of life for each clinical outcome based on the published study by Gage et al., 25 who reported that the utility after disabling ischaemic stroke was 0.39 using the time tradeoff methods. We thus assumed that the utility after disabling ICH was also 0.39. The in uence of the assumption in the utility calculation was examined by sensitivity analyses (Table 1) . 
Costs
All costs were expressed in 2001 US dollars. We estimated the direct cost of screening with palpation using the following formula:
Cost per person = This is equal to 60 exams per hour at one minute per exam. We estimated the cost for screening with ECG using the following formula:
Cost per person = Using expert opinion (six technologists experienced in taking ECG at annual health check-up and six physicians in reading ECG taken at annual health check-ups in Kyoto Preventive Medical Center), we assumed that the number of screening subjects on whom a technologist can take an ECG per hour is 15 and the number of ECG records a physician ( can read per hour is 200. We derived the personnel expenses of physicians and medical technologists from a salary survey reported by the National Personnel Authority. 26 In addition, we assumed a time cost for residents who attend a screening programme. Since no surveys were ever conducted on these costs, we used expert opinion (four technologists and two physicians) and assumed that the time necessary to attend screening programme was one hour with a margin. This time is converted to costs based on a salary survey reported by the National Personnel Authority. We took the following costs into account in our model: the cost of of ce visits after the detection of AF, echocardiography, monitoring of INR level, and warfarin use. 27, 28 We derived the costs of acute ischaemic stroke, ICH and gastrointestinal haemorrhage from the Diagnosis Related Groups (DRG) report in Japan. 29 We also derived the costs of care based on long-term care insurance for disabilities from the report by the Ministry of Health and Welfare (http://www.mhlw.go.jp/).
Discount rate
Quality-adjusted life-years, life expectancy and costs were discounted 3% per year.
Sensitivity Analyses
To assess the robustness of the model results, we conducted sensitivity analyses to examine the effects of uncertain parameters over reasonable ranges (Table 1) . Epidemiological data and costs were varied from half to double the base-case values. Sensitivity and speci city of palpatory examination, compliance and utilities were varied within clinically signi cant ranges. To examine the in uence of the age of the target population on cost-effectiveness of annual screening programmes, we changed the age from 65 years to 75 years. Each of these cohorts was followed-up until 85 years, after which age no epidemiological data are available. In addition, we examined the in uence of different screening intervals, ranging from every year to every ve years. Table 2 shows the results of the base-case analysis on male and female residents. In males, both annual ECG screening and palpation screening were more costly and at the same time more effective compared with no screening strategy.
RESULTS
Base-case analysis
Their incremental cost-effectiveness ratios were approximately US$8000 per QALY. This gure was favourable in the context of conventional criteria for cost-effectiveness (US$50,000 per QALY; Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; available at http://www.nhlbi.nih. gov/guidelines/cholesterol/atp3_rpt.htm). If 1000 hypothetical residents participated in annual screening programmes, they could avoid eight ischaemic stroke events but would suffer one more ICH due to anticoagulant therapy.
ECG screening and palpation screening had similar costs and produced almost the same life expectancy (LE) and QALYs. Palpation screening, when performed on 1000 hypothetical residents with the 1% prevalence of AF, would avoid 780 times of ECG, saving US$361.
When annual programmes were compared with no screening strategy in females, incremental LEs and incremental QALYs were slightly smaller than those in males. The incremental cost-effectiveness ratios of both annual screenings strategies compared with no screening strategy were approximately US$10,000 per QALY. Table 3 shows the results of the sensitivity analyses. Sensitivity analyses for the cost-effectiveness of the two annual screening methods compared to no screening showed similar results. The results were sensitive to the incidence of ischaemic stroke and anticoagulant prescription rate. When the incidence of ischaemic stroke was reduced to half of base-case value, or anticoagulants prescription rate from 100% to 30%, the incremental cost-effectiveness ratio became approximately US$40,000 per QALY. Relative risk reduction of ischaemic stroke and age of target population were also sensitive to the results. Changing other variables did not in uence the results. When the age of the target population was changed from 65 years to 75 years, the incremental cost-effectiveness ratios were slightly increased both in male and female residents.
Sensitivity analyses
With a longer screening interval, the reduction in effectiveness was trivial compared with that in cost ( Table  4 ). The incremental cost-effectiveness ratio increased rapidly as the screening interval became shorter.
DISCUSSION
AF is one of the major risk factors for ischaemic stroke. Early detection of this arrhythmia can lead to the use of anticoagulant therapy to prevent ischaemic stroke. It is possible to diagnose AF in patients who visit clinics periodically because of such chronic diseases as valvular disease, hypertension, and ischaemic heart disease. When people without chronic illness develop AF, however, not all of them seek medical care for that. Annual screening programmes using ECG or pulse palpation can detect individuals with newly developed AF. Screening programmes to detect AF were not recommended in the past. It was only in 2002 that the American Heart Association endorsed periodic of ce-based screening (case-nding). 30 However, case-nding for AF patients was reported to be less effective than systematic screening. 31 In Japan, an annual ECG screening programme has been offered to community residents as part of routine health services sine 1983. Therefore, we tried to estimate the effectiveness and cost-effectiveness of this programme.
Our results demonstrated that the incremental costeffectiveness ratios of both annual screening programmes compared with no screening strategy met the conventional criteria to be cost-effective and that sensitivity analyses on many variables did not change the results. In addition, the incremental cost-effectiveness ratios were smaller than those of such screening programmes in Japan as breast cancer (US$49,700 per QALY), 32 cervical cancer (US$40,600 per QALY), 33 colon cancer (US$13,100 per QALY) 34 and comparable to those of screening programmes of gastric cancer (US$4970-12,600 per QALY). 35 These cancer screening programs for community residents are provided under the domestic law 15 and two to six million residents are screened by these programs every year. Both annual screening programmes to detect chronic AF may therefore be accepted as a way of health promotion for community. However, there are some criticisms against recommendation based on incremental cost-effectiveness ratios without recognition of resource allocation 36 .
In our study, ECG and palpation screening showed similar cost-effectiveness in nding AF in undetected subjects because the sensitivity of palpation for detecting AF is nearly perfect (97.8%). Some modi cations in AF screening can be made to reduce the cost. For example, nurses instead of physicians can perform palpation and experienced medical technologists instead of physicians can read ECGs at screening sites.
The cost-effectiveness of screening the older population is less favourable than that of screening the younger population, in spite of the increasing prevalence of AF with age. The following explanation is possible: with increasing age, the period during which the target population gains bene t from screening would decrease, resulting in reduced costeffectiveness.
Biennial screening or lower-intensity screening programs were more favourable in terms of cost-effectiveness than annual screening programs. Although the incremental costeffectiveness for both annual and biennial screening programs met the conventional criteria for cost-effectiveness, policy makers might prefer lower-intensity screening programs because of favourable cost-effectiveness. The current study has some limitations. First, we had limited data on the incidence of AF in Japan. This is an important variable, but sensitivity analyses showed that even if the incidence of AF was decreased to half the basecase value, annual screening strategies continue to met the conventional criteria to be cost-effective. It is mandatory, however, for us to gather epidemiological data on the incidence of AF in Japan. Second, the natural history of AF could be more complex than the Markov model dictates in this analysis. Spontaneous recovery to sinus rhythm may occur, or cardiac events such as heart failure or acute coronary syndrome may develop. Third, some AF patients have contraindication for anticoagulant therapy or preference for anti-platelet therapy. A very low prescription rate of anticoagulants is likely to aggravate the cost-effectiveness. Fourth, the effectiveness of anticoagulant therapy has not been veri ed by a high-quality study in Japan. A recent RCT from Japan 37 suggested that the optimal intensity of anticoagulant therapy for Japanese patients with AF is slightly lower than the current recommendation in Western countries. [10] [11] [12] Fifth, we took into account only direct costs and time costs for screening programmes. It would be necessary to determine the xed costs as well.
In summary, this analysis demonstrated that annual screening programmes by either ECG or pulse palpation were a simple and cost-effective way to manage AF among community residents.
